Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSPNASDAQ:GMABNASDAQ:ILMNNASDAQ:INCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$47.49+1.7%$39.48$30.04▼$63.68$4.10B1.751.85 million shs15.07 million shsGMABGenmab A/S$20.50-1.1%$20.98$17.24▼$28.56$13.15B0.961.22 million shs727,649 shsILMNIllumina$94.79+0.7%$82.69$68.70▼$156.66$15.01B1.332.13 million shs3.84 million shsINCYIncyte$68.37-3.4%$64.49$53.56▼$83.95$13.23B0.671.97 million shs3.50 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics0.00%+7.32%+31.77%+39.55%-12.07%GMABGenmab A/S0.00%-3.12%-2.05%+4.70%-18.42%ILMNIllumina0.00%+4.75%+16.49%+19.47%-9.19%INCYIncyte0.00%-0.13%+4.78%+12.91%+12.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRSPCRISPR Therapeutics2.9337 of 5 stars4.31.00.00.01.92.50.6GMABGenmab A/S4.0064 of 5 stars3.35.00.00.02.90.03.1ILMNIllumina4.8394 of 5 stars4.23.00.04.22.83.31.3INCYIncyte4.329 of 5 stars2.13.00.03.12.52.53.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.53Moderate Buy$71.7551.08% UpsideGMABGenmab A/S 2.67Moderate Buy$37.6083.41% UpsideILMNIllumina 2.47Hold$127.3934.39% UpsideINCYIncyte 2.22Hold$74.539.01% UpsideCurrent Analyst Ratings BreakdownLatest CRSP, ILMN, GMAB, and INCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025CRSPCRISPR TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.006/27/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.006/27/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.006/26/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/26/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$82.006/24/2025ILMNIlluminaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight ➝ Underweight$77.00 ➝ $85.006/23/2025INCYIncyteRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetSector Perform ➝ Sector Perform$67.006/16/2025INCYIncyteStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$75.00 ➝ $107.006/11/2025ILMNIlluminaCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$87.00 ➝ $99.006/3/2025INCYIncyteCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/3/2025INCYIncyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$61.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$37.31M109.92N/AN/A$22.64 per share2.10GMABGenmab A/S$3.12B4.21$1.52 per share13.52$8.04 per share2.55ILMNIllumina$4.37B3.43$4.69 per share20.21$14.96 per share6.34INCYIncyte$4.24B3.12$0.55 per share123.50$17.90 per share3.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)GMABGenmab A/S$1.14B$1.7611.6511.526.7635.11%18.08%14.52%8/14/2025 (Estimated)ILMNIllumina-$1.22B-$6.07N/A18.371.86-22.25%25.54%8.62%8/5/2025 (Estimated)INCYIncyte$32.62M$0.32213.6610.450.580.48%2.77%1.77%7/29/2025 (Estimated)Latest CRSP, ILMN, GMAB, and INCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025GMABGenmab A/S$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million5/8/2025Q1 2025ILMNIllumina$0.96$0.97+$0.01$0.82$1.03 billion$1.04 billion5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/A4/29/2025Q1 2025INCYIncyte$1.01$1.16+$0.15$0.80$996.17 million$1.05 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AGMABGenmab A/SN/AN/AN/AN/AN/AILMNIlluminaN/AN/AN/AN/AN/AINCYIncyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR TherapeuticsN/A15.6415.64GMABGenmab A/SN/A5.345.32ILMNIllumina0.631.861.48INCYIncyte0.012.042.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%GMABGenmab A/S7.07%ILMNIllumina89.42%INCYIncyte96.97%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.10%GMABGenmab A/S1.54%ILMNIllumina0.17%INCYIncyte17.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics47386.36 million82.82 millionOptionableGMABGenmab A/S2,682641.22 million631.35 millionOptionableILMNIllumina9,030158.30 million158.03 millionOptionableINCYIncyte2,617193.57 million159.12 millionOptionableCRSP, ILMN, GMAB, and INCY HeadlinesRecent News About These CompaniesKBC Group NV Reduces Stock Position in Incyte Corporation (NASDAQ:INCY)4 hours ago | marketbeat.com23,678 Shares in Incyte Corporation (NASDAQ:INCY) Acquired by Sovran Advisors LLC4 hours ago | marketbeat.comIllinois Municipal Retirement Fund Reduces Holdings in Incyte Corporation (NASDAQ:INCY)June 28 at 5:17 AM | marketbeat.comDiversified Trust Co Sells 6,555 Shares of Incyte Corporation (NASDAQ:INCY)June 28 at 4:56 AM | marketbeat.comIncyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?June 27 at 10:37 PM | investors.comIncyte’s Promising Phase 3 Study on Ruxolitinib Cream for Hidradenitis SuppurativaJune 27 at 12:09 PM | tipranks.comIncyte’s Phase 3 Study on Povorcitinib: A Potential Game-Changer for Prurigo NodularisJune 27 at 12:09 PM | tipranks.comIncyte’s Ruxolitinib Cream Study: A Potential Game-Changer for Pediatric VitiligoJune 27 at 12:09 PM | tipranks.comIncyte’s Phase 3 Study on Axatilimab: A Potential Game-Changer for cGVHD TreatmentJune 27 at 12:09 PM | tipranks.comIncyte’s Ruxolitinib Cream Study: A Potential Game-Changer in Pediatric DermatologyJune 27 at 12:09 PM | tipranks.comIncyte’s New Study on INCB177054: A Potential Game-Changer in Cancer Treatment?June 27 at 12:09 PM | tipranks.comIncyte’s Challenges and Potential Amid Leadership Change and R&D HurdlesJune 27 at 7:32 AM | tipranks.comIncyte Corporation (NASDAQ:INCY) Shares Acquired by Robeco Institutional Asset Management B.V.June 27 at 5:01 AM | marketbeat.comIncyte Corporation (NASDAQ:INCY) Sees Stake Increased Nasdaq CompositeJune 26, 2025 | kalkinemedia.comKIncyte replaces CEO Hoppenot with dealmaker MeuryJune 26, 2025 | biopharmadive.comBIncyte stock rises as William Blair reiterates market perform ratingJune 26, 2025 | investing.comIncyte’s Leadership Transition and Pipeline Uncertainty Justify Hold RatingJune 26, 2025 | tipranks.comIncyte Appoints Bill Meury Chief Executive OfficerJune 26, 2025 | contractpharma.comCThe long game for weight loss drugs, allegedlyJune 26, 2025 | statnews.comSIncyte stock rises after appointing Bill Meury as new CEOJune 26, 2025 | investing.comIncyte waves goodbye to longtime CEO Hervé Hoppenot as new appointment raises M&A hopesJune 26, 2025 | fiercepharma.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRSP, ILMN, GMAB, and INCY Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$47.49 +0.79 (+1.69%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$47.95 +0.46 (+0.97%) As of 09:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Genmab A/S NASDAQ:GMAB$20.50 -0.23 (-1.11%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$20.43 -0.07 (-0.32%) As of 09:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Illumina NASDAQ:ILMN$94.79 +0.63 (+0.67%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$95.62 +0.82 (+0.87%) As of 09:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.Incyte NASDAQ:INCY$68.37 -2.44 (-3.45%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$68.31 -0.06 (-0.09%) As of 09:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
